Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.60 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.60 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31678688 | 0.77 | PTGS2 (0.50) | CYP11B1CYP11B2CYP19A1CYP17A1PTGS1 | |
| SCHEMBL11083179 | 0.76 | CYP11B1 (0.52) | CYP11B1CYP11B2CYP19A1CYP17A1PTGS1 | |
| SCHEMBL4514804 | 0.76 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP17A1CYP1A2 | |
| SCHEMBL7495373 | 0.70 | PTGS2 (1.00) | PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL8328212 | 0.69 | PTGS2 (0.97) | PTGS1PTGS2 | |
| SCHEMBL678387 | 0.69 | NPC1 (0.56) | CYP1A2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL677803 | 0.69 | CYP2A6 (0.44) | CYP19A1CYP2A6 | |
| SCHEMBL16539483 | 0.69 | LMNA (0.51) | ALDH1A1KMT2A | |
| SCHEMBL30473120 | 0.67 | CYP2A6 (1.00) | CYP11B1CYP11B2CYP19A1CYP17A1CYP1A2 | |
| SCHEMBL29419014 | 0.67 | CYP2A6 (1.00) | CYP11B1CYP11B2CYP19A1CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2166841-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | Mission Pharmacal Company (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | VIP, PDE3B, ADCY5 | CYP11B1 713/4885CYP11B2 839/4885CYP19A1 3112/4885 |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | VIP, PDE3B, ADCY5 | CYP11B1 713/4885CYP11B2 839/4885CYP19A1 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.